Vlado Perkovic's Publications

• Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbAinf1cinf, disease duration and treatment intensity: results from the CANVAS Program

  Journal articles

  2021

  Diabetologia

• Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial

  Journal articles

  2021

  European Heart Journal

• Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial

  Conference Papers

  2021

  EUROPEAN HEART JOURNAL

• Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial

  Journal articles

  2021

  Diabetologia

• Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis

  Journal articles

  2021

  The Lancet

• Urate-lowering Therapy for Prevention of Gout: Prespecified Analyses from the CKD-FIX Trial

  Conference Papers

  2021

  ARTHRITIS & RHEUMATOLOGY

• Effects of canagliflozin on major adverse cardiovascular events by baseline albuminuria: integrated analyses from the CANVAS Program and CREDENCE trial

  Conference Abstracts

  2021

  DIABETOLOGIA

• Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephroticrange proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial (Clinical Kidney Journal (sfaa225) DOI: 10.1093ckjsfaa225)

  Journal articles

  2021

  Clinical Kidney Journal

• Effect of hemodiafiltration on the progression of neuropathy with kidney failure: A randomized controlled trial

  Journal articles

  2021

  Clinical Journal of the American Society of Nephrology

• Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis

  Journal articles

  2021

  Diabetes, Obesity and Metabolism

• Chronic kidney disease

  Journal articles

  2021

  The Lancet

• Statistical Analysis Plan for the Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING)

  Preprints

  2021

• Current status of health systems financing and oversight for end-stage kidney disease care: A cross-sectional global survey

  Journal articles

  2021

  BMJ Open

• Canagliflozin, serum magnesium and cardiovascular outcomesAnalysis from the CANVAS Program

  Journal articles

  2021

  Endocrinology, Diabetes and Metabolism

• The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial

  Conference Abstracts

  2021

  Diabetes, Obesity and Metabolism

• ASCEND-ND: STUDY DESIGN AND BASELINE CHARACTERISTICS

  Conference Papers

  2021

  NEPHROLOGY DIALYSIS TRANSPLANTATION

• A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LNP023 IN PRIMARY IGA NEPHROPATHY PATIENTS

  Conference Abstracts

  2021

  NEPHROLOGY DIALYSIS TRANSPLANTATION

• Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex in the CREDENCE Trial

  Journal articles

  2021

  DIABETES

• The Impact of Canagliflozin on the Risk of Neuropathy Events: Results from the CREDENCE Trial

  Journal articles

  2021

  DIABETES

• Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: Post hoc analysis from the ADVANCE trial

  Journal articles

  2021

  Diabetes, Obesity and Metabolism

• Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease

  Journal articles

  2021

  Clinical Pharmacology and Therapeutics

• MO559ASCEND-ND: STUDY DESIGN AND BASELINE CHARACTERISTICS

  Journal articles

  2021

  Nephrology Dialysis Transplantation

• MO148A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LNP023 IN PRIMARY IGA NEPHROPATHY PATIENTS

  Journal articles

  2021

  Nephrology Dialysis Transplantation

• Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial

  Journal articles

  2021

  Circulation

• EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR EVENTS BY BASELINE ALBUMINURIA: INTEGRATED ANALYSIS FROM THE CANVAS PROGRAM AND CREDENCE TRIAL

  Journal articles

  2021

  NEPHROLOGY DIALYSIS TRANSPLANTATION

• Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program

  Journal articles

  2021

  Clinical Kidney Journal